Weifeng Xu
Merck & Co., Inc.
Dr. Weifeng Xu has been in the field of immunogenicity for more than 10 years. Previously at BMS and now at Merck, Dr. Xu has developed multiple neutralization Antibody assays for some of the major pipelines such as Opdivo, Yervory. At Merck, Dr. Xu is leading a Cell Assay Group within PPDM Regulated BA and has developed multiple neutralization antibody assays as well as infectivity assays for vaccine pipelines such as oncolytic virus and more recent, COVID-19 vaccine. He is currently an active member in AAPS NAb work group as well as EBF (European Bioanalysis Forum) NAb team; he is also co-leading the NAb assay drug tolerance subteam at AAPS.